



## ITOC-2 MEETING REPORT

CDDF is back from a successful 2nd Immunotherapy of Cancer Conference (ITOC-2). This meeting is growing rapidly into a global platform for translational research in the field of immuno-oncology. Organized by the Cancer Drug Development Forum, the ITOC conference series aims to provide a forum for discussion of early clinical drug development and address its unique challenges.

For this second edition, the conference again has surpassed our expectations in terms of attendance and participants. Our excellent scientific programme with an international faculty focused on many topics such as immunomodulatory agents, anti-cancer vaccines, adoptive and engineered T-cell Therapy and monoclonal antibodies with special emphasis on translational research and biomarker development.

### PLENARY SESSIONS

ITOC-2 presented plenary sessions on “Immune Suppression and Microenvironment”, “Checkpoint Inhibition”, “Combination Therapy”, “Immunomodulatory Agents”, “Anti-cancer Vaccines”, “Monitoring of Immunotherapy”, “Adoptive T-Cell Therapy”, and “Engineered T-Cell Therapy”.

A keynote lecture was given by **Prof. Alexander M.M. Eggermont**, Institut Gustave Roussy (France) on *Combining Immunomodulatory and/or Targeted Agents*.

### SATELLITE SYMPOSIA AND POSTER SESSIONS

The scientific programme of ITOC-2 was completed with:

- Four sponsored satellite symposia:
  - “Cancer Immunotherapy: translating innovative science into clinical trials” – F.Hoffmann-La Roche
  - “Broadening the horizon of Immuno-Oncology in 2015: Melanoma, lung cancer and beyond” – Bristol-Myers Squibb
  - “Checkpoint Inhibition: Transforming Breakthrough Science into Better Patient Care” – Merck MSD
  - “CARs and Cell Therapy: Today and the Road Ahead” – Novartis
- Eight Poster Sessions which tackled topics such as “Microenvironment and Inflammation”, “Immunosuppression”, “Therapeutic Modulation of Immune Checkpoints”, “Anti-cancer Vaccines”, “Antibody Therapy”, “Engineered T-cell Therapy”, “combination Therapy”, “Monitoring of Immunotherapy”.

### POSTER AWARDS

The poster awards were sponsored by the Munich Tumor Center and given to:



**Winner – Mrs Sc. L. POSSELT**, Klinikum der Universität München, Munich, Germany

Poster: *“Therapy of Hepatocellular Carcinoma (HCC) with Immunostimulatory RNA Activating RIG-I.”*

**Runner-up – Mrs C-I. URECHE**, Hannover Medical School, Germany

Poster: *“Redirecting Adenovirus-Specific T Cells by a Tumour-Specific T Cell Receptor for Therapy of Hepatocellular Carcinoma.”*

**Third Place – Ms S. KARAKHANOVA**, University of Heidelberg, Germany

Poster: *“Immunosuppressive Microenvironment in Pancreatic Adenocarcinoma.”*

Join us again in Munich next year!

**SAVE THE DATE**



[www.itoc-conference.eu](http://www.itoc-conference.eu)  
[www.cddf.org](http://www.cddf.org)